676 related articles for article (PubMed ID: 19389022)
1. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.
Osselaer JC; Doyen C; Defoin L; Debry C; Goffaux M; Messe N; Van Hooydonk M; Bosly A; Lin JS; Lin L; Corash L
Transfusion; 2009 Jul; 49(7):1412-22. PubMed ID: 19389022
[TBL] [Abstract][Full Text] [Related]
2. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment.
Osselaer JC; Messe N; Hervig T; Bueno J; Castro E; Espinosa A; Accorsi P; Junge K; Jacquet M; Flament J; Corash L
Transfusion; 2008 Jun; 48(6):1061-71. PubMed ID: 18346019
[TBL] [Abstract][Full Text] [Related]
3. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period.
Cazenave JP; Isola H; Waller C; Mendel I; Kientz D; Laforêt M; Raidot JP; Kandel G; Wiesel ML; Corash L
Transfusion; 2011 Mar; 51(3):622-9. PubMed ID: 20849406
[TBL] [Abstract][Full Text] [Related]
4. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
[TBL] [Abstract][Full Text] [Related]
5. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion.
Rasonglès P; Angelini-Tibert MF; Simon P; Currie C; Isola H; Kientz D; Slaedts M; Jacquet M; Sundin D; Lin L; Corash L; Cazenave JP
Transfusion; 2009 Jun; 49(6):1083-91. PubMed ID: 19309473
[TBL] [Abstract][Full Text] [Related]
6. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
[TBL] [Abstract][Full Text] [Related]
7. Release of immune modulation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment.
Cognasse F; Osselaer JC; Payrat JM; Chavarin P; Corash L; Garraud O
Transfusion; 2008 May; 48(5):809-13. PubMed ID: 18298593
[TBL] [Abstract][Full Text] [Related]
8. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
Seghatchian J; Hervig T; Putter JS
Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
[TBL] [Abstract][Full Text] [Related]
9. Trends in the utilization of blood components in San Pablo Hospital; 1991-1996.
Hunter Mellado R
Bol Asoc Med P R; 1997; 89(1-3):4-8. PubMed ID: 9168628
[TBL] [Abstract][Full Text] [Related]
10. Reducing the financial impact of pathogen inactivation technology for platelet components: our experience.
Girona-Llobera E; Jimenez-Marco T; Galmes-Trueba A; Muncunill J; Serret C; Serra N; Sedeño M
Transfusion; 2014 Jan; 54(1):158-68. PubMed ID: 23656485
[TBL] [Abstract][Full Text] [Related]
11. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
[TBL] [Abstract][Full Text] [Related]
12. Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats.
Ciaravino V; Hanover J; Lin L; Sullivan T; Corash L
Transfusion; 2009 May; 49(5):985-94. PubMed ID: 19175545
[TBL] [Abstract][Full Text] [Related]
13. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies.
Picker SM; Schneider V; Gathof BS
Transfusion; 2009 Jun; 49(6):1224-32. PubMed ID: 19220821
[TBL] [Abstract][Full Text] [Related]
14. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation.
Hechler B; Ohlmann P; Chafey P; Ravanat C; Eckly A; Maurer E; Mangin P; Isola H; Cazenave JP; Gachet C
Transfusion; 2013 Jun; 53(6):1187-200. PubMed ID: 23067365
[TBL] [Abstract][Full Text] [Related]
15. Implementation of buffy coat platelet component production: comparison to platelet-rich plasma platelet production.
Levin E; Culibrk B; Gyöngyössy-Issa MI; Weiss S; Scammell K; LeFresne W; Jenkins C; Devine DV
Transfusion; 2008 Nov; 48(11):2331-7. PubMed ID: 18631169
[TBL] [Abstract][Full Text] [Related]
16. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components.
Sigle JP; Infanti L; Studt JD; Martinez M; Stern M; Gratwohl A; Passweg J; Tichelli A; Buser AS
Transfusion; 2013 Aug; 53(8):1788-97. PubMed ID: 23176347
[TBL] [Abstract][Full Text] [Related]
17. Automated preparation of platelet concentrates from pooled buffy coats: in vitro studies and experiences with the OrbiSac system.
Larsson S; Sandgren P; Sjödin A; Vesterinen M; Gulliksson H
Transfusion; 2005 May; 45(5):743-51. PubMed ID: 15847664
[TBL] [Abstract][Full Text] [Related]
18. Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial.
Pineda A; McCullough J; Benjamin RJ; Cable R; Strauss RG; Burgstaler E; Porter S; Lin L; Metzel P; Conlan MG;
Transfusion; 2006 Apr; 46(4):562-71. PubMed ID: 16584432
[TBL] [Abstract][Full Text] [Related]
19. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.
Ambruso DR; Thurman G; Marschner S; Goodrich RP
Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996
[TBL] [Abstract][Full Text] [Related]
20. Patient and product factors affecting platelet transfusion results.
Heim D; Passweg J; Gregor M; Buser A; Theocharides A; Arber C; Meyer-Monard S; Halter J; Tichelli A; Gratwohl A
Transfusion; 2008 Apr; 48(4):681-7. PubMed ID: 18208413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
